Oblimersen

Drug Profile

Oblimersen

Alternative Names: Augmerosen; BCL-2 antisense oligonucleotide - Genta; G 3139; GC 3139; Genasense; Oblimersen sodium

Latest Information Update: 09 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Pennsylvania
  • Developer Genta; Genta (CEASED); National Cancer Institute (USA)
  • Class Antineoplastics; Antisense oligonucleotides; Thionucleotides
  • Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Malignant melanoma; Chronic lymphocytic leukaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Liver cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 31 Dec 2011 Discontinued - Phase-I for Solid tumours in USA (SC)
  • 31 Dec 2011 Discontinued - Phase-I/II for Solid tumours in USA (IV)
  • 31 Dec 2011 Discontinued - Phase-II for Breast cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top